Small molecules facing loss of developed market exclusivity 2011-2020
This statistic shows the loss through small molecule patent expiries in developed pharmaceutical markets from 2011 to 2020. In 2011, there was a total loss in exclusivity of 16 billion U.S. dollars among small molecule products in developed markets. Patent expiries reached a peak in 2012 when Lipitor, Plavix, Singulari, and Seroquel experienced competition from generics in the United States.
